Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/PEP.0000000000000763 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Guyton's hemodynamic mosaic: crafting fluid management with precision.
Ann Intensive Care
January 2025
Intensive Care Department, Hospital Israelita Albert Einstein, Av. Albert Einstein, 627/701 - Morumbi, São Paulo, CEP: 05651-901, SP, Brasil.
Sheldon Magder's article on applying Arthur Guyton's principles to clinical fluid management provides valuable insights into optimizing hemodynamics in critically ill patients. While emphasizing the role of right atrial pressure (RAP) in assessing cardiac output, challenges arise due to RAP's variable accuracy and the oversimplification of cardiovascular dynamics. Integrating RAP with dynamic assessments and bedside ultrasound can enhance fluid management strategies.
View Article and Find Full Text PDFCommentary: Endoscopic Coronary Arterial Bypass: Strike A Balance.
J Chest Surg
January 2025
Department of Thoracic and Cardiovascular Surgery, oneDOC Co. Ltd., Seoul, Korea.
Lowering blood pressure with continuous positive airway pressure: a work in progress.
Eur Respir J
January 2025
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA
Vascular-Adipose Crosstalk: Angiogenesis and Adipose Tissue Remodeling.
Circ Res
January 2025
Division of Cardiovascular Medicine, Department of Medicine (T.P.F., K.-V.T.), University of Massachusetts Chan Medical School, Worcester, MA.
Overlap Syndrome (COPD and OSA): A Treatable Trait for Triple Treatment?
Pulm Ther
January 2025
MSc Program in Sleep Medicine, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
The coexistence of chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA) in the same patient is referred to as overlap syndrome (OS). Patients with OS suffer more frequently from cardiovascular disease (CVD) and carry a higher risk of COPD-related exacerbations than patients with COPD alone, especially when OSA is left untreated. Based on recent evidence, triple therapy, namely inhaled corticosteroid/long-acting muscarinic antagonist/long-acting beta-agonist (ICS-LABA-LAMA), is a treatment strategy in COPD patients with a history of exacerbations and/or CVD comorbidity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!